Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 12/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.40 |
| ▸ | RET | P07949 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.35 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.35 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KDM4B | O94953 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19459124 | 0.99 | TLR9 (0.40) | TLR9TLR7TLR8RETPARP1 | |
| SCHEMBL19459081 | 0.91 | RET (0.41) | TLR9TLR7TLR8RETKIT | |
| SCHEMBL25777871 | 0.91 | RET (0.38) | TLR9TLR7TLR8RETKIT | |
| SCHEMBL25778277 | 0.89 | TLR9 (0.39) | TLR9TLR7TLR8PARP1KIT | |
| SCHEMBL19482443 | 0.86 | RET (0.41) | RETKITBMPR1BBMPR1AACVR1B | |
| SCHEMBL19459153 | 0.86 | RET (0.40) | TLR9TLR7TLR8RETKIT | |
| SCHEMBL19486477 | 0.85 | KCNH2 (0.38) | TLR9TLR7TLR8PARP1KIT | |
| Hydrochloric Acid SCHEMBL27218024 | 0.84 | RET (0.36) | TLR9TLR7TLR8RETKIT | |
| SCHEMBL19459216 | 0.83 | RET (0.39) | RETKITBMPR1BBMPR1AACVR1B | |
| SCHEMBL19481784 | 0.83 | TLR9 (0.41) | TLR9TLR7TLR8RETPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| US-20240158398-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2024-05-16 | — | — | US | disclosed |
| EP-4285996-A2 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | disclosed |
| US-11634422-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634422-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220315585-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2022-10-06 | — | — | US | disclosed |
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2020-01-30 | — | — | US | disclosed |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2020-01-30 | — | — | US | disclosed |
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3442977-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
| WO-2017181117-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017181117-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669277-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | TLR9 3810/4885TLR7 4204/4885TLR8 3425/4885 |
| US-20240158398-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | TLR9 3810/4885TLR7 4204/4885TLR8 3425/4885 |
| US-20200031830-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | TLR9 3810/4885TLR7 4204/4885TLR8 3425/4885 |
| US-11634422-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | TLR9 3810/4885TLR7 4204/4885TLR8 3425/4885 |
| US-10233186-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVR2A, ACVRL1 | TLR9 3803/4885TLR7 4225/4885TLR8 3727/4885 |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVRL1, ACVR2A | TLR9 3644/4885TLR7 3457/4885TLR8 3325/4885 |
| US-20170298069-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | TLR9 3810/4885TLR7 4204/4885TLR8 3425/4885 |
| US-20220315585-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | ACVR1, ACVR2A, ACVRL1 | TLR9 3810/4885TLR7 4204/4885TLR8 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.